EchoGo® Heart Failure was developed with Mayo Clinic.
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky

EchoGo® Amyloidosis is the first AI screening tool to help detect Cardiac #Amyloidosis using #EchoFirst. Seamlessly integrating into clinical workflows, it supports timely identification and intervention. 👉 www.ultromics.com/products/ech... #MedSky #CardioSky

❓ Test your knowledge:

Cardiac #Amyloidosis is challenging to diagnose, often requiring a high degree of clinical suspicion. Early recognition of red flags, including non-cardiac indicators, is critical for timely diagnosis and effective treatment. #CardioSky #MedSky

We’ll be at THT in 3 weeks, we're excited to discuss EchoGo® Heart Failure, 0ur AI-powered tool that helps detect #HFpEF & Cardiac #Amyloidosis from a routine echocardiogram. Meet us to learn how EchoGo® is transforming #HeartFailure care. www.ultromics.com/about/events #MedSky #CardioSky

Innovation is at the forefront of our mission to drive an AI revolution in the detection and diagnosis of heart failure. Learn more about our ground-breaking studies here: www.ultromics.com/hubfs/Ultrom... #CardioSky #MedSky

We’re excited to share our latest research & innovation at several events this year. Ultromics is transforming cardiology with advanced AI that supports #HFpEF and Cardiac #Amyloidosis detection. Upcoming events: www.ultromics.com/about/events #EchoGo #MedSky #CardioSky

EchoGo® Heart Failure is eligible for reimbursement in both inpatient & outpatient settings & includes
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.

💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91

👉https://www.ultromics.com/about/reimbursement